Ridaifen-B is primarily studied for its potential applications in cancer research due to its ability to induce apoptosis in cancer cells. It has shown promise in targeting specific pathways involved in cell survival and proliferation, making it a candidate for developing anti-cancer therapies. Additionally, Ridaifen-B has been explored for its role in modulating estrogen receptors, which could be beneficial in treating hormone-dependent cancers. Its unique mechanism of action sets it apart from traditional treatments, offering a novel approach to combating resistant cancer types. Research is ongoing to further understand its efficacy, safety, and potential therapeutic applications.